IKBKB and neoplasm: Studies have found that the deletion of the inhibitor kappa-B kinaseβ (IKKβ) in epithelial cells decreases tumor incidence, and the deletion of IKKβ in myeloid cells decreases tumor size, indicating that inactivating the IKK/NF-κB alters the formation of inflammation-associated tumors [152].